No Data
No Data
Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Has A Somewhat Strained Balance Sheet
Zhejiang Garden Biopharmaceutical (300401.SZ): The price of the main raw material for Vitamin D3 production is currently fluctuating slightly.
On July 26, Gelunhui reported that an investor asked Zhejiang Garden Biopharmaceutical (300401.SZ) on the investor interaction platform, "Has the production material for vitamin D3 increased in price?" The company replied that the main production material for vitamin D3 has currently experienced only minimal price fluctuations.
Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Zhejiang Garden Biopharmaceutical (300401.SZ): The designed annual production capacity of the fodder-grade Vitamin D3 product of the company is 3600 tons.
Zhejiang Garden Biopharmaceutical (300401.SZ) stated on the investor interaction platform on June 27 that the design capacity of the company's fodder grade VD3 product is 3,600 tons per year. The core competitiveness of the company's vitamins sector mainly includes: a clear industry chain, leading production technology, lower production costs, prominent business scale and good market channel construction.
Why Investors Shouldn't Be Surprised By Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) 31% Share Price Surge
Zhejiang Garden Biopharmaceutical (300401.SZ): Subsidiary Luo Hongming Pian was granted a pharmaceutical registration certificate.
On June 25th, Gelunhui reported that Zhejiang Garden Biopharmaceuticals (300401.SZ) announced that its wholly-owned subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd. (hereinafter referred to as "Garden Pharmaceutical "), recently received the Drug Registration Certificate of "Roxithromycin Tablets" approved and issued by the National Medical Products Administration. Roxithromycin tablets are mainly used to treat infections caused by roxithromycin-sensitive pathogens. Roxithromycin tablets are a type B variety in the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug List (2023)."
No Data